CKD-FIX: A Randomised, Controlled Trial Of Allopurinol In The Slowing Of Kidney Disease Progression
Funder
National Health and Medical Research Council
Funding Amount
$1,917,147.00
Summary
Chronic kidney disease (CKD) is a major public health problem affecting over 1.5 million Australians and is associated with increased risk of death, heart disease and progression to end-stage kidney disease (ESKD). Current treatments to slow progression to ESKD are limited. The CKD-FIX trial aims to find out whether treatment with allopurinol, a commonly used drug for gout prevention, safely and effectively slows CKD progression. This could lead to significant health and economic benefits.
Randomised Controlled Trial To Determine Efficacy And Safety Of Prescribed Water Intake To Prevent The Progression Of Autosomal Dominant Polycystic Kidney Disease (PREVENT-ADPKD)
Funder
National Health and Medical Research Council
Funding Amount
$746,751.00
Summary
Increasing the daily intake of water is well known to reduce the risk of developing kidney stones but there is growing evidence that it may also benefit other kidney diseases, particularly autosomal dominant polycystic kidney disease (ADPKD). This study will determine if adequate hydration can slow the progression of ADPKD, and could provide a relatively simple and cheap treatment for preventing the onset of kidney failure due to this disease.
Targeting PI3K-regulated MicroRNAs To Treat Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$532,593.00
Summary
Current therapeutics largely delay heart failure progression rather than regressing it. New therapeutic strategies with the capability of improving function of the failing heart are thus greatly needed. The primary goal of this study is to determine whether novel regulatory genes can enhance cardiac function in a setting of heart failure. Ultimately, technologies that target these genes may lead to innovative pharmacotherapies in the clinical management of heart failure.
Discovery Early Career Researcher Award - Grant ID: DE120100796
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
Androgens and ovarian function. This innovative project aims to identify the role androgens play in the complex processes required for successful ovarian follicle development and ovulation. The project aims to identify androgen regulated pathways that orchestrate follicle development, which will have significance in the control of fertility and the advancement of reproductive technologies.
Life-saving chemo/radio-therapy commonly renders women and girls who survivor cancer infertile or sterile. We have discovered a new means of preserving the fertility of female mice exposed to chemo/radio therapy. In this project we will apply these advances to human ovarian tissue/eggs for the first time. We have access to these rare tissues for research purposes. This project will develop new approaches to fertility preservation for cancer survivors.
Targeted Disruption Of Lipoxygenase Enzymes To Prevent Oxidative Stress-mediated Pathologies In The Male Germline
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
An estimated 80 million individuals suffer from infertility globally with at least 50% of these cases due to defects in sperm function. Unfortunately, due to a severe lack of knowledge surrounding sperm biology and dysfunction, no successful curative or preventative measures have been established. My project will study why sperm cells die and investigate new ways to limit cellular stress so we can develop new therapeutic strategies to mitigate the growing problems in male reproductive health.
Rapidly giving intravenous fluid to prevent or treat shock (fluid resuscitation) is one of the commonest treatments given to critically ill patients. Current guidelines recommend crystalloid solutions but it is unknown whether any particular crystalloid is better than others. This trial will determine whether the use of one of two crystalloid fluids, saline or PlasmaLyte, reduces the risk of organ injuries, such as kidney failure, and improves patients chances of surviving critically illness.
Centre Of Research Excellence: Partnering With Patients With Chronic Kidney Disease To Transform Care And Outcomes (CRE-PACT)
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
CRE-PACT will partner with patients to generate and translate new high-priority evidence to improve outcomes that are important to people living with chronic kidney disease (CKD). We will address the topics and questions most important to patients. We will build the next generation of research leaders and a community of research-ready patient-partners. There will be an integrated pathway for evidence translation and implementation at a global scale to improve patient-centred outcomes.
I-HEART - Implementation Of HEArt Failure Guidelines In Regional AusTralia
Funder
National Health and Medical Research Council
Funding Amount
$1,266,173.00
Summary
Heart failure (HF) is a common disease of the heart with a high rehospitalisation and mortality rate. Regional HF patients rarely receive the full benefits of evidence-based care simply due to inaccessibility to a HF specialist team. This translational project will implement key recommendations from clinical guidelines in regional health services and improve access to specialist services. It has the potential to keep patients out of hospital and save lives.
Advanced Heart Failure Management With Ventricular Assist Therapy – Evaluating Australian Costs Of Care And Effectiveness From Implant To Transplant Or End Of Life
Funder
National Health and Medical Research Council
Funding Amount
$45,668.00
Summary
Ventricular Assist Devices (VADs) are implantable heart pumps that are increasingly being used to slow down the progression of end stage heart failure. This project assesses the costs and effectiveness of VAD therapy and advanced heart failure medical management in an Australian health care setting. The aim is to provide Australian clinicians and health decision makers access to current and relevant, clinical, cost and effectiveness data for advanced heart failure and VAD therapy.